Blog - INTERNET MÉDICA

Hematologia Pediátrica: Artigos de Revisão ( Pediatric Hematology: Reviews)

Por Paulo Leite 08/11/2021

■ Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leucemia

Meinolf Suttorp, Frédéric Millot, Stephanie Sembill et al

Cancers (Basel) 2021, vol 13(4): 798

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917817/

■ Thrombocytosis in children and adolescents – classification, diagnostic approach, and clinical management

Clemens Stockklausner, C. M. Duffert, H. Cario et al

On behalf of THROMKID-Plus Studiengruppe der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) and of Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)

Ann Hematol 2021; vol 100(7): 1647–1665

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195939/

■ Risk and response adapted treatment guidelines for managing relapsed and refractory classical Hodgkin lymphoma in children and young people. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group

S Daw, D Hasenclever, M Mascarin et al

Hemasphere 2021, vol 4 (1): e329

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7000476/

■ Iron deficiency anemia in children residing in high and low-income countries: risk factors, prevention, diagnosis and therapy

Elpis Mantadakis, Eleftherios Chatzimichael, Panagiota Zikidou

Mediterr J Hematol Infect Dis.2020; vol 12(1): e2020041

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7340216/

■ Interventions for addressing anemia among children and adolescente: an overview of systematic reviews

Prasanna Mithra, Mahalaqua Nazli Khatib, Anju Pradhan Sinha et al

Front Pediatr.2020; vol 8: 549549

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7921152/

■ Immunization adherence in children with sickle cell disease: a single-institution experience

Lisa M. Infanti, Joshua J. Elder, Kyle Franco et al

J Pediatr Pharmacol Ther.2020, vol 25(1): 39–46

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938294/

■ Review and emerging targeted therapies for pediatric acute myeloid leucemia (AML)

Jing Chen, Chana L. Glasser

Children (Basel) 2020, vol 7(2): 12

https://www.mdpi.com/2227-9067/7/2/12/htm

■ Advances in pediatric acute promyelocytic leukemia

Shannon E. Conneely, Alexandra M. Stevens

Children (Basel) 2020, vol 7(2): 11

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7072343/

■ Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemia

Seth E. Karol, Ching-Hon Pui

Ther Adv Hematol 2020, vol 11:2040620720927575.

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7268159/

■ Harnessing T cells to target pediatric acute myeloid leucemia: CARs, BiTEs, and beyond

Rebecca Epperly, Stephen Gottschalk, Mireya Paulina Velasquez

Children (Basel) 2020, vol 7(2): 14

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7072334/

■ Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa

Nmazuo W. Ozuah, Joseph Lubega, Carl E. Allen, Nader Kim El-Mallawany

Blood Adv 2020, vol 4(16): 4007–4019

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448606/

■ Manejo analgésico da crise dolorosa falciforme não complicada em pediatria: uma revisão sistemática e metanálise.

Saramba, Manou Irmina, Shakya, Sandeep and Zhao, Dongchi

Pediatr. (Rio J.), Apr 2020, vol.96, no.2, p.142-158

https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572020000200142&lng=pt&nrm=iso&tlng=pt (portuguese)

https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0021-75572020000200142&lng=pt&nrm=iso&tlng=en (english)

S Daw, D Hasenclever, M Mascarin et al

Hemasphere 2021, vol 4 (1): e329

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7000476/

■ Gene therapy of the hemoglobinopathies

J B Kunz, A E Kulozik

Hemasphere 2020, vol 4 (5): e479

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7489710/

■ Venous thromboembolism in childhood: where is Brazil after 20 years

T T Mello, H D A Carneiro, G A Mello, J M A Bizzacchi

Hematol, Trans. Cell Ther 2020, vol 42 (1)

https://www.scielo.br/j/htct/a/6Cth9CkCZ7fs3WZjhvxDfcp/?lang=en

■ Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population

F Carobolante, S Chiaretti, C Skert, R Bassan

Ther Adv Hematol 2020, vol 11: 2040620720903531

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC6997963/

■ Fetal hemoglobina in sickle hemoglobinopathies: high HbF genotype and phenotypes

Martin H. Steinberg

J Clin Med.2020, vol 9(11): 3782

https://ashpublications.org/blood/article/118/1/19/28401/Fetal-hemoglobin-in-sickle-cell-anemia

■ Current issues and options ,for hormonal contraception in adolescents and young adult women with sickle cell disease: an update for health care professionals

Vincenzo De Sanctis, Ashraf T. Soliman, Shahina Daar et al

Mediterr J Hematol Infect Dis.2020; vol 12(1): e2020032.

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7202337/

■ Bleeding complications after pediatric kidney biopsy: a systematic review and meta-analysis

Charles D. Varnell, Jr., Hillarey K. Stone, Jeffrey A. Welge

Clin J Am Soc Nephrol 2019, vol 14(1): 57–65

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364534/

■ Pulmonary hemosiderosis in children with Down syndrome: a national experience

Aurelia Alimi, Jessica Taytard, Rola Abou Taam et al

Orphanet J Rare Dis.2018; vol 13: 60

https://ojrd.biomedcentral.com/articles/10.1186/s13023-018-0806-6

■ Deficiência de ferro na criança

J A P Braga, M S S Vitalle

Rev Bras Hematol Hemot 2010, vol 32 (suppl 2)

https://www.scielo.br/j/rbhh/a/QWdTYfPCzqVNKjTWHjmGw3M/?lang=pt

■ Dr Paulo Fernando Leite

Cardiologia/Prevenção Cardiovascular

Consultório: Rua Padre Rolim 815/sala 601 – Belo Horizonte/MG/Brasil

Tel: 33245518

CRMMG: 7026

Email: pfleite1873@gmail.com

Blog Internet Médica – www.internetmedica.com.br

Data: novembro 2021

Policitemia Vera (Polycythemia Vera)

Por Paulo Leite 05/11/2021

– A policitemia vera (PV) é uma doença mieloproliferativa crônica, caracterizada pela proliferação de precursores hematopoéticos, principalmente da série eritróide. Ela se caracteriza por medula óssea hipercelular. É o mais comum dos distúrbios mieloproliferativos, com uma incidência de aproximadamente 2/100000 pessoas. O diagnóstico de PV torna necessária a exclusão de causas secundárias. A flebotomia é o tratamento primário para a PV. A hidroxiuréia, interferon e anagrelídeo para citorredução ficam reservados para os pacientes com trombocitose persistente ou que correm um maior risco de eventos tromboembólicos. Os portadores de PV em vários centros hematológicos apresentaram longa sobrevida. Os eventos trombóticos arteriais foram a principal complicação em portadores de policitemia vera.

– A eritrocitose secundária é um aumento da massa de glóbulos vermelhos causada por um estímulo à produção dessas células, podendo ocorrer por um processo de hipoxemia crônica. Em nosso meio, as causas mais frequentes de eritrocitose secundária a hipoxemia são as cardiopatias cianogênicas e a doença pulmonar obstrutiva crônica. Essas condições resultam em uma menor oxigenação tecidual, o que estimula uma maior produção de eritropoietina pelos rins, através do fator de transcrição induzível pela hipóxia. A eritrocitose ocorre para um melhor fornecimento de oxigênio aos tecidos, mas acaba por causar hiperviscosidade sanguínea, que por sua vez leva a diversos sintomas e a um maior risco trombótico.

■ Polycythemia vera: update on emerging treatment options

Giulia Benevolo, Francesco Vassallo, Irene Urbino, Valentina Giai

Ther Clin Risk Manag.2021; vol 17: 209–221

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981161/

■ Advances in the treatment of polycythemia vera: trends in disease management

Yajur Arya, Arshi Syal, Monica Gupta, Saurabh Gaba

Cureus.2021, vol 13(3): e14193.

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8084584/

■ Emerging agents and regimens for polycythemia vera and essential thrombocythemia

Rory M. Shallis, Nikolai A. Podoltsev

Biomark Res.2021; vol 9: 40

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8161993/

■ Lemierre´s syndrome in an elderly female patient wity polycythemia vera: Does polycythemia predispose to Lemierre´s syndrome?

Sanchit V. Kundal, Jasmine Lee, Mazin Khalid et al

Am J Case Rep.2021; vol 22: e933587-1–e933587-5

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8488186/

■ Transformation of polycythemia vera to pure erythroid leukemia

Louisa Liu, Neil Dudheker, Lhara M Sumarriva Lezama et al

Cureus.2021, vol 13(7): e16168

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8330807/

■ Ginostat: an emerging treatment for polycythemia vera

Helen T. Chifotides, Prithviraj Bose, Srdan Verstovsek

Expert Opin Investig Drugs. 2020 Jun; 29(6): 525–536

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7534842/

■ Recents advances in prognostication and treatment of polycythemia vera

B K Marcelino, R Hoffaman

Fac Rev 2021, vol 10: 29

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8009192/

■ Interferon alpha therapy in essential thrombocythemia and polycythemia vera – a systematic review and meta-analysis

Jan Philipp Bewersdorf, Smith Giri, Rong Wang et al

Leukemia.2021, vol 35(6): 1643–1660

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7917159/

■ Investigation and management of erythrocytosis

S Mithoowani, M Laureano, M A Crowther, C M Hillis

CMAJ 2020, vol192 (32) E913-E918

https://www.cmaj.ca/content/192/32/E913

■ Ruxotilinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis

Arianna Masciulli, Alberto Ferrari, Alessandra Carobbio, Arianna Ghirardi, Tiziano Barbui

Blood Adv.2020, vol 4(2): 380–386

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC6988397/

■ Is there a gender effect in polycythemia vera?

Francesca Palandri, Barbara Mora, Naseema Gangat, Lucia Catani

Ann Hematol.2021, vol 100(1): 11–2

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7782364/

■ Recent advances in the use of molecular analyses to inform the diagnosis and prognosis of patients with polycythaemia vera

Ruth Stuckey, María Teresa Gómez-Casares

Int J Mol Sci.2021, vol 22(9): 5042

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8126083/

■ Evaluation of therapeutic strategies to reduce the number of thrombotic events in patients with polycythemia vera and essential thrombocythemia

Douglas Tremblay, Heidi E. Kosiorek, Amylou C. Dueck, Ronald Hoffman

Front Oncol.2020; vol 10: 636675

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7921696/

■ Avaliação e tratamento da eritrocitose secundária a hipóxia crônica

S T F Grunewald

Rev Med Minas Gerais 2019, vol 29: e-2026

http://www.rmmg.org/artigo/detalhes/2588

■ Non-enhanced CT mimicking contrast enhanced CT – a case report on polycythemia

Pooja Varwatte, Gurubharath Ilangovan, Harshavardhan Balganeshan et al

J Radiol Case Rep.2019, vol 13(4): 10–16

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC6743642/

■ Update in the management of polcythemia vera and essential thrombocythemia

Prithviraj Bose, Srdan Verstovsek

Ther Adv Hematol.2019; vol 10: 2040620719870052

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC6719465/